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DIRECT PRICE CONTROL ON PATENTED DRUGS IN INDIA:
THE PROBABLE EFFECTS ON INNOVATION AND ACCESS TO
MEDICINES
Ajay Prasad*, Varsha lyengar**
Addressing the growing concern stemmingfrom the issue of access to and
affordability of drugs, this articlearguesfor the use of a direct price control
mechanism to prevent the abuse of monopoly rights emergingfrom the
patenting of pharmaceuticalproducts. The article also demonstrates the
limited utility of compulsory licensing in achieving access to medicines,
and explodes the myth of direct price control necessarily hindering
innovation, consequentlyputtingforwardapersuasivecasefor reformulating
and rigorouslyimplementing India'shithertoimpotent price control regime
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1. INTRODUCTION
"As we enjoy great advantagesfrom the inventions of others, we should be
glad of an opportunity to serve others by any invention of ours; and this we
should do freely andgenerously."
- Benjamin Franklin.
The imposition of price controls on drugs in India has been a topic of much
debate, more so after the introduction of product patents for medicines and drugs
in 2005. The new patent regime inspired by TRIPS' has led to growing concerns
*
**

.

IV year, B.A.LLB. (Hons.). Student, University Law College, Bangalore.
IV year, B.A.LLB. (Hons.). Student, University Law College, Bangalore.
AgreementonTrade-Related Aspects of Intellectual Property RightsApr.15,1994, Marrakesh
Agreement Establishing the World Trade Organization, Annex 1C, Legal Instruments Results of the Uruguay Round, 33 .L.M. 1125,1197 (1994).
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about the accessibility and affordability of patented drugs in India. The government
has been dismissing these concerns by citing drug price regulations and compulsory
licensing as tools to tackle the problem of high prices? The pharmaceutical industry
in India, on the other hand, has been strongly critical of the direct price control
mechanisms? It claims that direct price controls hinder research and development,
the safeguarding of which is the main object of granting patent protection. However,
there is also a strong lobby for the strengthening of the drug price control
mechanisms to make them more effective in reducing the high prices of patented
drugs. This paper analyses the role of the drug price control mechanism in India

as a tool to increase the access to and affordability of medicines while avoiding
the adverse effects of price control on Research and Development (R&D). Part I of
this paper examines the drug price control mechanism that is prevalent in the

country. Part II analyses the effect of direct price control on patented drugs. Part
III deals with the effect of price control on R&D and innovation, and Part IV
concludes the paper with a brief overview of upcoming laws and policies and
suggestions about their functioning.

II. PATENT LAW

AND DRUG PRICE CONTROL MECHANISMS:
AN OVERVIEW

The law of patents was first introduced in India through the Indian Patents
Act, 1856) This Act was subject to many amendments over the years and was
finally repealed to give way to the Indian Patents and Designs Act, 1911. After
India's independence in 1947, theGovernment appointed the Tek Chand Committee
and the Ayyangar Committee to review patent laws? The reports of these
committees recognised the need to strengthen indigenous industries, considering
that India ranked high in epidemic disease prevalence, poverty and drug prices.6
Following this, the Tek Chand Committee recommended the introduction of
compulsory licensing to curb the abuse of monopoly by the patent holder! The
2.
3.
4.

Kamal Nath, Statement on the Ordinance Relating to Patents (Third) Amendment
(Dec. 27, 2004), available at http://pib.nic.in/release/ release.asp?relid=6074.
Pharma Industry Opposes Price Control Mechanism, Bus. LmN, Jan. 11, 2007, available at
http://www.ficci.com/news/viewnewsl.aspnews_id=855.
History of Indian Patent System, available at http://www.patentoffice.nic.in/ipr/patent/
history.htre.

5.

Raghavan, The First Ten Years of the TRIPS Agreement: Of the Inequals of The Uruguay
Round, 10 MARQ. INTELL. PROP. L. REV. 273, 273-274 (2006).

6.

Id.

7.

Raghavan, supra note 5.
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Ayyangar Committee recommended that only process patents be granted for
medicines and food. The Committee reasoned that these products were essential
and steps should be taken to make them available at low and affordable prices?
The recommendations of these two committees suited the needs of an underdeveloped India and were, therefore, extremely influential in the formulation of
India's patent policy. They were consequently incorporated in the Indian Patents
Act, 1970 which only allowed for the grant of process patents for food, medicines
and drugs? This law was in effect until 2005, till India amended the Indian Patents
Act, 1970 and allowed product patents for food, medicines and drugs in order to
make Indian law TRIPS-compliant. The present patent law is, thus, TRIPScompliant and provides for product and process patents for all inventions which
meet the criteria under the Indian Patents Act, 1970.
Drug price control has existed in India ever since the Third Five Year Plan. 0
The failure of the Third Five Year Plan led to introduction of the Drug Price Control
Order of 1970 (DPCO).' The DPCO allowed the government control over drug
prices, thus complementing the compulsory license provisions." The liberalisation
of the economy in 1991 and India's WTO membership led to the Drug Price Control
Order, 1995.13 The Drug Price Control Order, 1995 and the Pharmaceutical Policy,
2002 constitute the current drug price control regime in India."
The Pharmaceutical Policy is under litigation before the Supreme Court for
aiming to reduce the number of drugs under the Drug Price Control Order, 1995.
8.

Raghavan, supra note 5.

9.

Raghavan, supra note 5, at 274-275.

10.

1961-1966 PLANNING CoMMissIoN, THEDn FIVE YEAR PLAN, ch. 32, 145, available at http://

11.

planningcommission.nic.in/plans/planrel/fiveyr/ default.htnl.
The Drug Price Control Order, 1970 was passed under The Essential Commodities
Act, 1955, available at http://indiacode.nic.in/fullactl. asp?tfnm=195510.

12.

See P. G. Sampath, Economic Aspects of Access to Medicines After 2005: Product Patent

Protectionand EmergingFirm Strategiesin the IndianPharmaceuticalIndustry,CommissIoN
INTELL. PRor. RTs. INNOVATION PuH. HEALTH, available at http://www.who.int/
13.

intellectualproperty/studies/ access_2005/en/index.html,
The Drug Price Control Order, 1995 availableat http://nppaindia.nic.in/ drug-price95/

txtl.html.
14. The Pharmaceutical Policy, 2002, availableat http://nppaindia.nic.in/may-2002/policy02.htnLThe DPCO is the main regulatory mechanism through which the prices of
the drugs are fixed and controlled. The National Pharmaceutical Pricing Authority
(NPPA) is the regulatory body which monitors and regulates the price of drugs
according to the provisions of the DPCO. The Pharmaceutical Policy, 2002 is a policy
which aims to amend the DPCO 1995 according to its aims and objectives, thus
renewing and amending the list of drugs under the DPCO 1995.
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Il.

DIRECT PRICE CONTROL: EFFECT ON ACCESS AND
AFFORDABILITY OF PATENTED DRUGS

With the introduction of product patents for drugs, the prices of patented
drugs have become a contentious issue. Studies estimate that drugs tend to be
priced higher when conferred product patents.17 Of special interest is a study by
Yale University and World Bank economists that estimates a rise of about 100% to
400% in prices when product patents are available to foreign firms without any
price regulation." Further, on account of exclusive rights granted under the patent,
the patent holder may have negligible competition, especially when the drug has
no substitutes. This can clearly be seen in the case of Clivec, a life-saving drug that
is used in treating cancer." Novartis was granted Exclusive Marketing Rights (EMR)
for the drug and it was priced at US $30 per capsule, whereas the generic version
of the drug, which only Natco Laboratories was allowed to manufacture, was priced
at US $1.5 per capsule, thus providing an affordable substitute for the drug.' The
removal of other generic substitutes from the market, as a result of the EMR allowed
Novartis to set the price at US $2000 for a month's treatment with Clivec, making
it unaffordable for the majority of the population." Thus, extreme price rise as a
15. Centre Adds 75 New Medicines to Essential List, Times of India, July 11, 2003, availableat
http://timesofindia.indiat imes.com/artideshow/71739.cms.
16. The Pharmaceutical Policy, 2006, Part A, available at http://pib.nic.in/archieve/others/
2005/documents2005dec/docu ments2005dec_chemfert.pdf.
17. See S. Chaudhuri et al, Estimatingthe Effects ofGlobal Patent Protection in Pharmaceuticals:
A Case Study of Quinolones in India (Nat'l Bureau of Econ. Research, Working Paper
No. 10159, 2003) availableat http://ssrn.com/abstract=478668; C. Fink, How Stronger
Patent Protection in India Might Affect The Behavior or Transnational Pharmaceutical
Industries(The World Bank, Working Paper no.2352,2000) available at http://ssm.com/
abstract=630724.
18. Chaudhuri et al., supra note 17, at 6.
19. Glivec (iminatib mesylate) is a drug used to treat chroni myeloid leukemia.
20. Sampath, supra note 12.
21. The Impact of India's Amended Patents Act on Access to Affordable HIV Treatment,
HEALTHGAP, Feb 2005, available at www.healthgap.org/press-releases/05/
020105_HGAPFS_INDIAIPR.pdf.
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result of the granting of product patent protection is a cause for concern, especially
with regard to the affordability and accessibility of drugs. Direct price control is a
tool that can provide an effective solution to these problems. It involves monitoring,
regulating and directly fixing the prices of drugs based on fixed criteria such as
annual sales turnover, reference pricing, essential medicines, etc.
The Pharmaceutical Policy and the DPCO have a common objective of
ensuring that essential drugs are available at reasonable prices? The Doha WTO
Ministerial Declaration in 2001 recognised that the exclusivity of patents should
not prevent governments from taking measures to protect public health, especially
by providing access to and ensuring the affordability of medicines.23 Thus, the
effectiveness of direct price control in India depends on factors like the criteria for
price control, the enforcement of these criteria and the concern for R&D while
providing for affordable and accessible drugs.
Price control measures are adopted to ensure that the product is available
at the lowest price to the public and that the price is not disproportionate to the
supply and the cost of production. Studies show that in India, even if a strict price
regulation maintains the price of patented drugs at the pre-product patent level,
the consumer will lose easy access? This is because the extensive marketing and
distribution networks of generic companies allow their products to be more readily

available to the consumer. Further, the consumer would also feel the loss of variety.
Direct price regulation, by itself, may not allow for easy access or greater
variety, but will still be useful for ensuring affordability? If the patented drug has

many substitutes in the market, then price regulation would be more effective if
accompanied by compulsory licensing. However, direct price control is more
advantageous than issuing compulsory licenses in certain situations. Compulsory
licenses are issued to any person interested in working the patented invention
and who has made an application to the controller of patents for the grant of such
license. Further, compulsory licenses are issued only on the basis of certain fixed
grounds 6 and are issued only after three years of granting the patent? Therefore,
22. See generally The Drugs Price Control Order, 1995; See also The Phamaceutical Policy,

2002.
23.

World Trade Organization, Declaration on the TRIPs Agreement and Public Health
of 14 November 2001, WT/MIN(01)/DEC/2, 41 LL.M. 755 (2002).

24. Chaudhuri, supra note 17, at 4.
25. Chaudhuri, supra note 17, at 4.
26. Section 84, Patents Act, 1970.
27. Section 24C, Patents Act, 1970.
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direct price control is the only tool that maintains the exclusive rights of the patent
holder, allowing the holder to optimise profits even while under price control.
Further, within the first three years, direct price regulations act as an effective tool
in preventing escalation in the prices of the patented drug. Another advantage of
direct price control is in respect of patented drugs which do not have many
substitutes, such as Anti Retro-Viral (ARV) drugs used for Human

Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS)
treatment. An ARV drug is the main treatment for HIV/AIDS, Though it is not a
cure, it is considered a life-saving treatment as it can help in increasing and
maintaining the immunity of a person living with HIV/AIDS, which is very
important to counter the effects of the disease. The prices of these drugs can be
controlled without the issuance of a compulsory license. Thus, direct price control
mechanisms can assist in increasing the affordability and accessibility of essential
drugs. However, the price control mechanisms in India have not quite achieved
these objectives. This is because of the poor implementation of direct price control
through the DPCO and the Pharmaceutical Policy, 2002.
A. De-control of Prices
A look at the drugs under the DPCO clearly shows that pricing, so far, has
hardly considered health policies and needs. The main function of the DPCO and
the Pharmaceutical Policy has been the de-control of drugs. The effect of de-control
on prices of essential drugs is seen in the following table2 1
NAME
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B. Criteria for Control
One of the reasons for the inefficiency of the DPCO in achieving its aim of
providing affordable and accessible medicines is the criteria on which the price is
fixed or controlled? According to the DPCO, the need for price control is based
on the minimum or total annual turnover of the medical drug or formulation?'
The DPCO does not base its criteria on the need for the drug in the country Due to
this, the life-saving drugs for HIV/AIDS and tuberculosis treatment are not on the
list. This is of critical importance as HIV/AIDS and tuberculosis patients often
need second line and third line treatment? This need arises often when the patient

becomes resistant to the drug after its repeated use, which is known as "cross
resistance". This necessitates the changing of treatment to include new drugs so
that the new drugs are not amongst those to which HIV has become resistant?
In India, only the first line and the second line treatment for HIV/AIDS is
freely available in those areas where these diseases are highly prevalent.M The
third line treatment is out of the scope of price control and is not provided freely
by the government. As a result, patients of HIV/AIDS as well as public health at
large are disadvantaged. Thus, the focus of drug pricing policies should shift
from the existing turnover based criteria to a need based criteria, in order to ensure
that the DPCO is successful in achieving the objective of affordability.

C. Price Regulation
With regard to price regulation, the National Pharmaceutical Pricing
Authority (NPPA) has the responsibility of tracking down price manipulations by
companies on a regular basis. Pharmaceutical companies currently indulge in large
scale price dodging by altering the pack sizes of drugs or the strength of
formulations. They also market non-standard pack sizes of syrups, tonics and
30. Sections 3 & 7, DPCO, 1995.
31. According to the DPCO, 'Bulk Drug' means means any pharmaceutical, chemical,
biological or plant product including its salts, esters, stereo-isomers and derivatives,
conforming to pharmacopoeial or other standards specified in the Second Schedule
to the Drugs and Cosmetics Act, 1940 (23 of 1940), and which is used as such or as an
ingredient in any formulation. A'formulation' means a medicine processed out of, or
containing without the use of any one or more bulk drug or drugs without
pharmaceutical aids, for internal or external use for or in the diagnosis, treatment,
mitigation or prevention in human beings but only includes allopathic drugs.
32. This is due to factors like non-compliance with the prescribed regime, non-availability
of prescribed drug or immunisation to the first line treatment.
33.

AIDS & HIV Antiretroviral Drug Treatment, available at http://www.avert.orgl

aidstreatment.htm.
34. The Government provides second line treatment only to those who prove resistant to
the first line treatment.
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creams for the purpose of escaping price control. However, the NPPA is unable
to function effectively as it is not well-equipped or adequately provided with the
requisite number of state departments. Thus, it falters in fixing prices of controlled
formulations on time and in the detection of any price control violations.
Further, the NPPA cannot regulate the prices of essential medicines, unless
they are included in the price control list that is in constant decline and has not
been reviewed in the past few years. Presently, under DPCO, 1995, there are 74
bulk drugs and their formulations under price control, that cover approximately
40% of the total market, The following table is illustrative of the decline.3'
Market share of drugs under the DPCO, 1979-2004
YEAR OF REVIEW

NUMBER OF DRus

APPROXIMATE MARKET SHARE
'(IN PERCENTAGE)

1979
1987
1995
2004
*

347
142
74
38*

80
60
40
20

Not yet effective

It is clear that direct price control shall remain a failed system if it is not
implemented intelligently. The reason that direct price control has not adequately
increased affordability and accessibility of medicines in India is because of the
aforementioned flaws in the DPCO and the Pharmaceutical Policy.

IV.

DIRECT PRICE CONTROL ON PATENTED DRUGS:

EFFECTS ON

R&D

AND INNOVATION

The pharmaceutical industry has been very vehement in its opposition to
the direct price control mechanism for drugs in India. 8 One of the reasons for
35. DodgingPrice Control,PHARMAB1z, Jan. 30, 2008, availableat http://www.pharmabiz.com/

article/detnews.afsp?articleid=42750&sectionid.
36. See Functionsof NPPA, availableat http://nppaindia.nic.in/indexleng.html (last visited
Mar. 21, 2008).

37. P Malhotra and H. Lofgren, India's PharmaceuticalIndustry: Hype Or High Tech Takeoff in TOWARDS A FuNCnONAL COMPETTON PouCY FOR INDiA: AN OVERVIEw 107 (M.S.
Pradeep ed., Academic Foundation in Association with Consumer Unity and Trust
Society 2005).
38. PharnaIndustry Opposes Price Control Mechanism, supra note 3.
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opposing the direct price control of drugs is that it leads to lower investment and
fewer R&D activities. That there is no correlation between direct price control
and R&D activities is evinced by the fact that there was no increase in investment
or R&D in the pharmaceutical sector even when the number of drugs subjected to
price control was reduced to 74.0
Prices have been seen to rise steeply after removing price control. The
argument that total price de control is necessary to ensure funds for R&D is
fallacious. A recent study found that the Indian pharmaceutical industry is one of
the most profitable industries in India, second only to the IT industry 1 The study
also found that one 6f the reasons for this excellent performance is that a major
part of these profits come from overcharging several drugs. R&D investment in
the drug industry continues to be less than 2% of sales."
The only area that needs encouragement is investment in the distribution
and marketing of patented drugs by foreign firms to make the drugs-more
accessible. 0 This can be conveniently done as it causes no harm to the profits or
the R&D of the patent holding company. In fact, price control mechanisms are
prevalent in many countries around the world -particularly in Europe - that are
renowned for R&D activities."
A. Comparison with other Countries
Price Control over medicines exists in some form in most countries. In
Australia, since 1993, new drugs with no advantage over existing products are
offered at the same price. Where clinical trials show superiority, incremental cost
effectiveness is assessed to determine whether a product represents value for money
at the price sought.0 In European countries such as Denmark, Greece, Finland,
Ireland, Italy, the Netherlands, Portugal, and Sweden, the maximum price of
39. Pharma Industry Opposes Price Control Mechanism, supra note 3.
40. Nanda & Khan, supra note 28, at 108.
41. Supra note 35.

42. Supra note 35.
43. See generally Chaudhuri, supra note 17. As mentioned above, domestic generic
companies are more accessible to the public as a result of wide marketing and
distribution networks.

44. See generally K.E. Bloor & N. Freemantle, Lessons from InternationalExperience in
Controlling PharmaceuticalExpenditure IT: Regulating Industry, 313, Brr. MEn. J. 1996

45.

33 35 (1996). In Netherlands, Germany, New Zealand and Sweden, reference pricing
is followed. In Spain, maximum prices are set for each product, comprising total cost
and company profit. France has a system of volume related price cuts.
Malhotra and Lofgren, supra note 37, at 97.
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medicines is set in relation to prices in neighbouring countries. In Belgium, France
and Italy, prices are set in relation to prices in the EU. Spain and the United
Kingdom set their prices to ensure a rateof return within a particular profit range."
In Canada, the Patented Medicine Prices Review Board (PMPRB), established
in 1987, limits the prices set by manufacturers for all patented medicines, new or
existing, sold in Canada, under prescription or over the counter, to ensure they
are not excessively priced. The PMPRB, an independent quasi-judicial tribunal,
was set up exclusively to monitor the prices of patented drugs. The PMPRB
regulates the price of each patented drug in the first and last month of every year.4 7
Even in the United States, where there is no official price control, there is a growing
demand from special interest groups calling for legislation to make pharmaceutical
drugs more affordable, either through legalized re-import from price-regulated
markets such as Canada and the E.U., or more directly through governmentimposed price controls."
In comparison, the need for a strict price control regime in a developing
country such as India can hardly be over-emphasized. Where, unlike in the
developed countries, expenditure on medicines constitutes a large proportion
(greater than 50%) of total medical expenditure and 90% of this expenditure is
out-of-pocket expenditure by the people," exercising control over prices of drugs
is of utmost importance. This is accentuated by the absence of basic healthcare
and a social security system in the country.

V. THE ROAD

AHEAD

The Pharmaceutical Policy by aiming to reduce the number of drugs under
price control, does not seem to take into account the need for cheap drugs in the

country and the effect of de-control on essential drugs. As mentioned above, the
Pharmaceutical Policy is under litigation before the Supreme Court of India as a

46. See generally A. Maynard and K. Bloor, Dilemmas In Regulation Of The Market For

Pharmaceuticals,available at http://content.healthaffairs.org/cgi/ content/full/22/3/31.
47. Malhotra and Lofgren, supranote 37, at 104.
48, See generally R.E. Santerre and J.A. Vernon, Assessing consumer gains from a drug price
control policy in the United States, available at http://goliath.ecnext.com/coms2/gi 0199-

5698626/Assessing-consumer-gains-from-a.html#abstract.
49.

S. Narain, PublicHealth-A Life Saving Order,availableat http://www.flonnet.com/fl2115/
stories/20040730 004110300.htm.
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result of a stay order of the High Court of Karnataka on the policy. The High
Court of Karnataka had previously decided that the Policy is arbitrary and against
Articles 14 and 21 of the Constitution.
The Supreme Court has directed the Central Government to "consider and
formulate appropriatecriteriafor ensuringessentialand life saving drugs not tofall out of
price control" ' Accordingly, the Central Government brought out the National
List of Essential Medicines, 2003 which contains 354 drugs." The Government
announced that these drugs would be under price control but did not implement
the same due to the opposition from the pharmaceutical industry.
The Central Government also brought out a part of the Pharmaceutical Policy,
2006, under which mandatory price negotiations for patented drugs are a
precondition to market approval." However, these negotiations are truly effective
only when performed with the participation of civil society. The Pharmaceutical
Policy, 2006 also provides for public-private partnership programmes for anticancer and anti-HIV/AIDS drugs. 3 But it is not clear why the programmes are
limited to only these diseases. The Pharmaceutical Policy, 2006 is currently under
review and has not been enforced.
The Central Government of India has now constituted the Sandhu
Committee that is looking to make drugs more accessible in the post-2005 patent
regime by re-defining the categories and basis for price control." The government
can also look at other solutions, like increasing government grants for R&D
activities to companies. The pharmaceutical companies on their part can enter
into strategic alliances with foreign firms that can facilitate their use of the foreign
players' superior R&D facilities and can also look at strengthening industryacademia linkups 5
It is clear that direct price control mechanisms are potential tools to counter
the abuse of monopoly on a patented drug. The Ayyangar Committee's view that
essential products such as medicines should be available at cheap and affordable
prices even with the grant of patents still holds good today.56 The advantages that
50.
51.

The Pharmaceutical Policy, 2006, supra note 16, at 1.
The Pharmaceutical Policy, 2006, supra note 16, at 1,

52. The Pharmaceutical Policy, 2006, supra note 16, at 11.
53.
54.
55.

The Pharmaceutical Policy, 2006, supra note 16, at 9-11.
Malhotra and Lofgren, supranote 37, at 111.
Malhotra and Lofgren, supra note 37.

56.

Raghavan, supra note 5, at 4.
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direct price controls offer should be used at the right time, especially when the
issuance of compulsory licenses is not possible. At the same time, if the flaws of
the DPCO, the Pharmaceutical Policy, 2002 and the NPPA are not corrected, direct
price control will prove to be an ineffective tool to ensure affordability and
accessibility of medicines. Steps such as reduction of de-control, provision for a
need-based criterion and improvement in the functioning of the NPPA will make
direct price control a stronger tool in making cheaper drugs available to the public.
However, at the same time, it should be ensured that these steps do not adversely
impact investment in R & D and innovation.
De-control of drug prices has succeeded in raising the prices of drugs but
has hardly resulted in a favourable impact on R&D activities.57 It is difficult to
determine how far direct price control will affect investment in R&D in the
pharmaceutical industry in the future. Much will depend on the nature of the
drug, the need for it in the country and the actual investment in R&D activities by
the patent holding company. Therefore, it becomes important that the law should
maintain a balance between the affordability of medicines and encouraging R&D
activities.

57.

See Nanda & Khan, supra note 28, at 108.
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